Literature DB >> 9823687

Emergence and epidemiology of vancomycin-resistant enterococci in Australia.

J Bell1, J Turnidge, G Coombs, F O'Brien.   

Abstract

Enterococci with acquired resistance to vancomycin and other glycopeptides (VRE) have emerged and spread rapidly through Europe and the United States since 1988. The first isolate of VRE in Australia occurred in 1994. Only one case was noted in 1995. Since March 1996 there has been a steady increase in the number of reports of VRE throughout the country. To August 1998 there have been 69 documented strains or clusters of strains detected in patients with documented infection, and about 3 times as many strains have been detected through screening procedures of contacts or in risk groups. 19% of strains whose source was known were blood isolates, while 34% came from urine and 47% came from other specimens. The strains have been found in 26 institutions in 10 widely separated cities or regions of the country (in 6/8 states or territories), without any obvious temporal associations in their appearance. All strains appear to have arisen locally except for one strain imported from the United Kingdom. Furthermore there was no direct evidence of interhospital transfer of strains. All clinical strains were examined by PCR to confirm species and to test for the presence of known vancomycin-resistance genes. Of the 69 strains, 42 were vanB E. faecium, 12 were vanA E. faecium, 9 were vanB E. faecalis, 3 were vanA E. faecalis. Three were negative for vanA, vanB, vanC1, vanC2/C3 and vanD. PGFE profiles on 38 strains have revealed at least 8 types of vanB E. faecium, 6 of vanA E. faecium, 4 of vanB E. faecalis and 2 of vanA E. faecalis. Isolates containing vanA always had different profiles from those containing vanB. Clinical clustering was confirmed by PFGE, and supported by extended antibiogram. 14 of 15 E. faecalis were ampicillin susceptible compared to only 2 of 54 E. faecium. One E. faecalis strain was beta-lactamase positive. The epidemiology of VRE in Australia appears to be different from that of Europe or the United States, since vanB E. faecium predominates and strains have appeared in diverse locations independently and are highly polyclonal.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823687

Source DB:  PubMed          Journal:  Commun Dis Intell        ISSN: 0725-3141


  10 in total

1.  Vancomycin-resistant enterococci in Canada revisited.

Authors:  B L Johnston; J M Conly
Journal:  Can J Infect Dis       Date:  2000-05

2.  Use of matrix-assisted laser desorption ionization-time of flight mass spectrometry to identify vancomycin-resistant enterococci and investigate the epidemiology of an outbreak.

Authors:  Paul M Griffin; Gareth R Price; Jacqueline M Schooneveldt; Sanmarié Schlebusch; Martyn H Tilse; Tess Urbanski; Brett Hamilton; Deon Venter
Journal:  J Clin Microbiol       Date:  2012-06-27       Impact factor: 5.948

3.  Comparative study of selective chromogenic (chromID VRE) and bile esculin agars for isolation and identification of vanB-containing vancomycin-resistant enterococci from feces and rectal swabs.

Authors:  E A Grabsch; S Ghaly-Derias; W Gao; B P Howden
Journal:  J Clin Microbiol       Date:  2008-10-01       Impact factor: 5.948

4.  Co-colonization by multidrug-resistant bacteria in two Greek intensive care units.

Authors:  M Papadimitriou-Olivgeris; I Spiliopoulou; M Christofidou; D Logothetis; P Manolopoulou; V Dodou; F Fligou; M Marangos; E D Anastassiou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2015-07-15       Impact factor: 3.267

5.  Low vancomycin MICs and fecal densities reduce the sensitivity of screening methods for vancomycin resistance in Enterococci.

Authors:  Thamara M Wijesuriya; Peta Perry; Todd Pryce; John Boehm; Ian Kay; James Flexman; Geoffrey W Coombs; Paul R Ingram
Journal:  J Clin Microbiol       Date:  2014-05-28       Impact factor: 5.948

6.  Risk factors for enterococcal infection and colonization by vancomycin-resistant enterococci in critically ill patients.

Authors:  M Papadimitriou-Olivgeris; E Drougka; F Fligou; F Kolonitsiou; A Liakopoulos; V Dodou; E D Anastassiou; E Petinaki; M Marangos; K S Filos; I Spiliopoulou
Journal:  Infection       Date:  2014-08-21       Impact factor: 3.553

7.  Molecular epidemiology of enterococcal bacteremia in Australia.

Authors:  Geoffrey W Coombs; Julie C Pearson; Denise A Daley; Tam Le; Owen J Robinson; Thomas Gottlieb; Benjamin P Howden; Paul D R Johnson; Catherine M Bennett; Timothy P Stinear; John D Turnidge
Journal:  J Clin Microbiol       Date:  2014-01-03       Impact factor: 5.948

8.  Improved detection of vanB2-containing enterococcus faecium with vancomycin susceptibility by Etest using oxgall supplementation.

Authors:  E A Grabsch; K Chua; S Xie; J Byrne; S A Ballard; P B Ward; M L Grayson
Journal:  J Clin Microbiol       Date:  2008-04-23       Impact factor: 5.948

9.  Prevalence and risk factors for VRE colonisation in a tertiary hospital in Melbourne, Australia: a cross sectional study.

Authors:  Surendra Karki; Leanne Houston; Gillian Land; Pauline Bass; Rosaleen Kehoe; Sue Borrell; Kerrie Watson; Denis Spelman; Jacqueline Kennon; Glenys Harrington; Allen C Cheng
Journal:  Antimicrob Resist Infect Control       Date:  2012-10-08       Impact factor: 4.887

10.  Molecular characteristics and predictors of mortality among Gram-positive bacteria isolated from bloodstream infections in critically ill patients during a 5-year period (2012-2016).

Authors:  Matthaios Papadimitriou-Olivgeris; Fevronia Kolonitsiou; Vasileios Karamouzos; Katerina Tsilipounidaki; Alexandra Nikolopoulou; Fotini Fligou; Markos Marangos; Efthimia Petinaki; Iris Spiliopoulou
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2020-01-02       Impact factor: 3.267

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.